Routes of
administration Oral CAS Number 916072-89-4 ChemSpider 28530803 Route Oral administration | ATC code None PubChem CID 135626906 Molar mass 570.6356 g/mol | |
 | ||
Legal status US: Investigational New Drug | ||
Naldemedine (INN, USAN; S-297,995) is a peripherally-selective μ-opioid receptor antagonist under development by Shionogi for the treatment of opioid-induced adverse effects including constipation, nausea, and vomiting. Clinical studies have thus far found it to possess statistically significant effectiveness for these indications and to be generally well-tolerated with predominantly mild to moderate gastrointestinal side effects. No effects indicative of central opioid withdrawal or impact on the analgesic or mydriatic effects of co-administered opioids have been observed. As of July 2014, naldemedine is in phase III clinical trials in the United States and Japan.
References
Naldemedine Wikipedia(Text) CC BY-SA